195 related articles for article (PubMed ID: 12892456)
1. Immunohistochemical study of the expression of drug-resistant proteins in large cell neuroendocrine carcinoma of the lung.
Okada D; Kawamoto M; Koizumi K; Tanaka S; Fukuda Y
Jpn J Thorac Cardiovasc Surg; 2003 Jul; 51(7):272-6. PubMed ID: 12892456
[TBL] [Abstract][Full Text] [Related]
2. Concurrent expressions of metallothionein, glutathione S-transferase-pi, and P-glycoprotein in colorectal cancers.
Sutoh I; Kohno H; Nakashima Y; Hishikawa Y; Tabara H; Tachibana M; Kubota H; Nagasue N
Dis Colon Rectum; 2000 Feb; 43(2):221-32. PubMed ID: 10696897
[TBL] [Abstract][Full Text] [Related]
3. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ
Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086
[TBL] [Abstract][Full Text] [Related]
4. Synovial sarcoma: immunohistochemical expression of P-glycoprotein and glutathione S transferase-pi and clinical drug resistance.
Lopes JM; Bruland OS; Bjerkehagen B; Silva MC; Holm R; Pettersen EO; Solheim OP; Sobrinho-Simões M; Nesland JM
Pathol Res Pract; 1997; 193(1):21-36. PubMed ID: 9112270
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of resistance-related proteins in human lung tumors with poor vascularization.
Koomägi R; Mattern J; Volm M
Carcinogenesis; 1995 Sep; 16(9):2129-33. PubMed ID: 7554065
[TBL] [Abstract][Full Text] [Related]
6. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases.
Jiang SX; Kameya T; Shoji M; Dobashi Y; Shinada J; Yoshimura H
Am J Surg Pathol; 1998 May; 22(5):526-37. PubMed ID: 9591721
[TBL] [Abstract][Full Text] [Related]
7. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases.
Takei H; Asamura H; Maeshima A; Suzuki K; Kondo H; Niki T; Yamada T; Tsuchiya R; Matsuno Y
J Thorac Cardiovasc Surg; 2002 Aug; 124(2):285-92. PubMed ID: 12167788
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of glutathione transferase-pi in untreated primary non-small-cell lung cancer.
Arai T; Yasuda Y; Takaya T; Hayakawa K; Toshima S; Shibuya C; Kashiki Y; Yoshimi N; Shibayama M
Cancer Detect Prev; 2000; 24(3):252-7. PubMed ID: 10975287
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes and incidence of brain metastases in pulmonary large cell neuroendocrine carcinoma.
Zhao Y; Castonguay M; Wilke D; Xu Z; Plourde M; Mulroy L; MacNeil M; Bowes D
Curr Probl Cancer; 2019 Feb; 43(1):54-65. PubMed ID: 30107896
[TBL] [Abstract][Full Text] [Related]
10. Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study.
Paci M; Cavazza A; Annessi V; Putrino I; Ferrari G; De Franco S; Sgarbi G
Ann Thorac Surg; 2004 Apr; 77(4):1163-7. PubMed ID: 15063227
[TBL] [Abstract][Full Text] [Related]
11. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy.
Saji H; Tsuboi M; Matsubayashi J; Miyajima K; Shimada Y; Imai K; Kato Y; Usuda J; Kajiwara N; Uchida O; Ohira T; Hirano T; Mukai K; Kato H; Ikeda N
Anticancer Drugs; 2010 Jan; 21(1):89-93. PubMed ID: 19770636
[TBL] [Abstract][Full Text] [Related]
12. Expression of glutathione S-transferase pi and glutathione synthase correlates with survival in early stage non-small cell carcinomas of the lung.
Allen TC; Granville LA; Cagle PT; Haque A; Zander DS; Barrios R
Hum Pathol; 2007 Feb; 38(2):220-7. PubMed ID: 17234469
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
[TBL] [Abstract][Full Text] [Related]
14. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi.
Mathieu A; Remmelink M; D'Haene N; Penant S; Gaussin JF; Van Ginckel R; Darro F; Kiss R; Salmon I
Cancer; 2004 Oct; 101(8):1908-18. PubMed ID: 15386340
[TBL] [Abstract][Full Text] [Related]
15. Behaviour and survival of high-grade neuroendocrine carcinomas of the lung.
Naranjo Gómez JM; Gómez Román JJ
Respir Med; 2010 Dec; 104(12):1929-36. PubMed ID: 20810262
[TBL] [Abstract][Full Text] [Related]
16. Clinical-pathologic analysis of 40 patients with large cell neuroendocrine carcinoma of the lung.
Dresler CM; Ritter JH; Patterson GA; Ross E; Bailey MS; Wick MR
Ann Thorac Surg; 1997 Jan; 63(1):180-5. PubMed ID: 8993262
[TBL] [Abstract][Full Text] [Related]
17. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology.
Iyoda A; Hiroshima K; Toyozaki T; Haga Y; Fujisawa T; Ohwada H
Cancer; 2001 Jun; 91(11):1992-2000. PubMed ID: 11391577
[TBL] [Abstract][Full Text] [Related]
18. Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.
Matsumura Y; Umemura S; Ishii G; Tsuta K; Matsumoto S; Aokage K; Hishida T; Yoshida J; Ohe Y; Suzuki H; Ochiai A; Goto K; Nagai K; Tsuchihara K
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2159-70. PubMed ID: 25989941
[TBL] [Abstract][Full Text] [Related]
19. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer.
Battafarano RJ; Fernandez FG; Ritter J; Meyers BF; Guthrie TJ; Cooper JD; Patterson GA
J Thorac Cardiovasc Surg; 2005 Jul; 130(1):166-72. PubMed ID: 15999058
[TBL] [Abstract][Full Text] [Related]
20. Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer.
Ikeda K; Sakai K; Yamamoto R; Hareyama H; Tsumura N; Watari H; Shimizu M; Minakami H; Sakuragi N
Int J Gynecol Cancer; 2003; 13(6):776-84. PubMed ID: 14675314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
